Respiratory
How NZ, Australian, and GOLD 2024 guidelines approach diagnosis, classification, and inhaler therapy for COPD - and where PHARMAC funded options shape what is practically achievable in NZ.
Scope: stable COPD management in primary care. Acute exacerbations covered in the exacerbation management row. Does not cover surgical or bronchoscopic interventions.
Where they agree
Where they diverge
Comparison
| Domain | NZ - BPAC 2021 | AU - COPDX 2023 | International - GOLD 2024 |
|---|---|---|---|
| Diagnosis | Post-bronchodilator spirometry with FEV1/FVC <0.70 in a patient with relevant symptoms (dyspnoea, chronic cough, sputum production) and/or risk factors (smoking, occupational exposure). Clinical diagnosis alone is insufficient. | Identical threshold. Spirometry is essential; underdiagnosis in primary care is explicitly flagged. COPDX emphasises confirming irreversibility to distinguish from asthma. | Post-BD FEV1/FVC <0.70. GOLD 2024 reiterates that a fixed ratio is practical but slightly overestimates obstruction in older adults. Confirms spirometry is required; symptom-only diagnosis is not acceptable. |
| Classification system | Uses severity grades (GOLD 1-4 by FEV1%) and ABCD groups based on symptoms (mMRC/CAT) and exacerbation history. BPAC 2021 predates the 2023 GOLD update that replaced ABCD with ABE. | COPDX 2023 incorporates an updated ABCD-derived framework. Emphasises individualised assessment of symptom burden and exacerbation risk as the primary treatment drivers. | GOLD 2024 uses ABE groups: Group A (low symptoms, low exacerbation risk), Group B (high symptoms, low risk), Group E (any exacerbation risk, regardless of symptom burden). Lung function grade (1-4) now used separately for prognosis and research, not to direct treatment initiation. |
| Initial therapy - low symptoms (Group A) | A short-acting bronchodilator used as needed. If persistent, step up to a long-acting bronchodilator. SABA (salbutamol) or SAMA (ipratropium) as first option.Funded | Short-acting bronchodilator as needed. Ipratropium preferred over SABA in some phenotypes. Early consideration of a long-acting agent if symptoms persist despite PRN use. | Group A: offer a bronchodilator (short- or long-acting) and reassess response. The choice of short vs long-acting is based on symptom persistence. Start with SABA or SAMA for intermittent symptoms. |
| Initial therapy - symptomatic (Group B) |
Long-acting bronchodilator monotherapy: prefer LAMA (tiotropium) or LABA (indacaterol).Funded In practice, tiotropium is the most commonly initiated long-acting agent in NZ primary care for symptomatic COPD. |
Long-acting bronchodilator monotherapy: LAMA preferred for most patients due to superior exacerbation prevention vs LABA alone. Dual LAMA/LABA (e.g. tiotropium + indacaterol/glycopyrronium) for persistent high symptom burden.PBS | Group B: LAMA or LABA, or LAMA/LABA. GOLD 2024 explicitly states that LAMA/LABA dual therapy should be considered as initial therapy for patients with high symptom burden (CAT ≥20 or mMRC ≥2), rather than waiting to step up. Single agent if symptoms are less severe. |
| Exacerbation prevention (Group E) |
Step up from LAMA to LAMA + ICS/LABA combination for patients with recurrent exacerbations. Separate inhalers required as single-device triple therapy is not funded.FundedSeparate inhalers only ICS-containing therapy (e.g. budesonide/formoterol or fluticasone/salmeterol) combined with tiotropium achieves triple coverage using two funded devices. |
LAMA/LABA as initial escalation. Triple therapy (ICS/LABA/LAMA) for persistent exacerbations despite dual bronchodilation, or if blood eosinophils >300 cells/µL.PBS Single-inhaler triple therapy devices (e.g. beclomethasone/formoterol/glycopyrronium; fluticasone furoate/umeclidinium/vilanterol) are PBS-listed in AU. |
Group E: LAMA/LABA as initial escalation. Consider adding ICS if blood eosinophils >300 cells/µL, or if on LAMA/LABA with ongoing exacerbations and eos 100-300 cells/µL. Triple therapy (ICS/LABA/LAMA) if further exacerbations on LAMA/LABA. De-escalate ICS if pneumonia risk is high or eos <100 cells/µL. |
| Blood eosinophils and ICS | BPAC 2021 notes that ICS should be added for patients with frequent exacerbations, but does not provide specific eosinophil count thresholds. Clinical judgement and exacerbation history guide the decision. | COPDX 2023 incorporates eosinophil-guided ICS decisions aligned with GOLD. Blood eosinophils >300 cells/µL: ICS is likely beneficial. Eosinophils <100 cells/µL: ICS benefit is minimal and pneumonia risk may outweigh it. |
GOLD 2024 provides explicit thresholds: <100 cells/µL: ICS unlikely to benefit; avoid 100-300 cells/µL: consider ICS if exacerbations persist despite dual BD >300 cells/µL: ICS strongly supported Peripheral blood eosinophils are a reliable biomarker for predicting ICS response in COPD.1 |
| Roflumilast | Not funded by PHARMAC. Cannot be prescribed in routine NZ practice without Special Authority or self-funding at significant cost.Not funded | PBS-listed. Indicated for severe COPD (FEV1 <50% predicted) with chronic bronchitis phenotype and frequent exacerbations (≥2/year), despite optimised inhaled therapy. Used as an add-on to bronchodilator therapy.PBS | Roflumilast (PDE4 inhibitor) reduces exacerbations in the chronic bronchitis phenotype with FEV1 <50% predicted and frequent exacerbations. GOLD 2024 recommends it as an add-on for this specific subgroup on maximal inhaled therapy. Side effects (nausea, weight loss) limit use. |
| Azithromycin prophylaxis | BPAC 2021 does not recommend routine azithromycin prophylaxis in primary care. Specialist consideration warranted for frequent exacerbators where other options are exhausted. | Specialist-initiated. Low-dose azithromycin (250mg three times weekly or 500mg daily) for former smokers with recurrent exacerbations refractory to optimised inhaled therapy. QTc and hearing assessment required before starting. | GOLD 2024: azithromycin prophylaxis (250mg daily or 500mg three times weekly) reduces exacerbation frequency in former smokers with recurrent exacerbations on maximal therapy. Contraindicated in current smokers (increased lung cancer risk). Cardiac and audiological monitoring required. |
| Pulmonary rehabilitation | Strongly recommended for all patients with mMRC ≥2 or significant functional limitation. Access in NZ is geographically uneven; community and hospital-based programmes vary in availability. Referral should be made when available. | Strongly recommended post-exacerbation (within 4 weeks of discharge) and for stable patients with mMRC ≥2. COPDX highlights that post-exacerbation PR reduces rehospitalisation. Telehealth-based PR increasingly available. | GOLD 2024: one of the most effective non-pharmacological interventions. Recommended after hospitalisation for exacerbation (within 4 weeks). Reduces symptoms, improves exercise capacity, and reduces hospital admissions. Home-based programmes are acceptable where supervised programmes are unavailable.2 |
| Exacerbation management | Increase SABA frequency. Prednisolone 40mg daily for 5 days if moderate-severe. Antibiotic only if purulent sputum plus increased dyspnoea or sputum volume (not for all exacerbations). Amoxicillin or doxycycline first-line.Funded | Largely aligned. Prednisolone 37.5-50mg daily for 5 days. Antibiotic only if bacterial exacerbation features present. Choice guided by local resistance and patient allergy history. Admission thresholds clearly defined. | GOLD 2024: prednisolone 40mg for 5 days (longer courses add adverse effects without benefit). Antibiotics only when bacterial features are present (purulent sputum, increased sputum, increased dyspnoea, or C-reactive protein >10 mg/L). Procalcitonin may guide antibiotic use. Avoid over-treating mild viral exacerbations. |
| Vaccinations | Annual influenza vaccine. Pneumococcal vaccination (13-valent then 23-valent, or 20-valent PCV). COVID-19 vaccination for all eligible patients. RSV vaccination should be discussed with eligible older adults.Funded | Influenza annually. Pneumococcal as per national schedule. Pertussis (dTpa) in some guidelines. COVID-19 for eligible patients. | GOLD 2024: influenza and pneumococcal vaccination strongly recommended. COVID-19 vaccination recommended. RSV vaccination (RSVpreF or mRNA-1345) recommended for adults aged 60 and over, including those with COPD. Pertussis vaccination in some populations. |
NZ clinical context
PHARMAC funding and population-specific considerations
PHARMAC funds a defined set of COPD inhalers. The practical pharmacotherapy ladder in NZ differs from what GOLD 2024 or COPDX describe because certain agents and combination devices are not funded.
BPAC NZ 2021 uses the GOLD ABCD classification system. GOLD updated its framework in 2023, replacing ABCD with ABE - where Group E captures all patients with significant exacerbation risk regardless of symptom level. This change emphasises that exacerbation risk should drive treatment escalation independently of symptoms. NZ clinicians using BPAC 2021 as their primary reference should be aware that GOLD 2024 recommendations (particularly for Group B initial therapy with LAMA/LABA dual bronchodilation) may not be reflected in current BPAC guidance. The practical implication is that GOLD 2024 is more aggressive about dual bronchodilation upfront in symptomatic patients.
COPD rates are disproportionately higher in Maori and Pacific populations in NZ, partly attributable to higher smoking prevalence historically, occupational exposures, and socioeconomic factors. Diagnosis is often delayed. Spirometry interpretation should account for the fact that reference ranges are derived predominantly from European cohorts; some have argued that fixed-ratio criteria may over-diagnose obstruction in some Pacific phenotypes, though this remains debated. Pulmonary rehabilitation access is often more limited in communities with higher Maori and Pacific COPD burden - consider telehealth or community options where available.
A reasonable PHARMAC-aligned treatment ladder for primary care:
Also see the COPD Management tool in the Workbench for a GOLD-staged inhaler guide with NZF-funded options.
Bottom line for NZ practice
What this means in the consulting room
Sources